News

Pharmaceutical companies need to replenish their portfolios. But are biologics the way to go? Part 2 of Nuala Moran's report from Düsseldorf.

The German Research Foundation is calling for the urgent revision of the country’s 2002 Stem Cell Act.

Just four out of ten Portuguese firms were actively investing in innovation between 2002 and 2004, according to a new report.

The innovation winners will have to use a more disciplined – and science-based – approach to garnering new ideas, says a leading consultant.

Booz Allen Hamilton’s second annual global innovation survey promises to continue last year's debate on the link between R&D spending and corporate performance.

A French start-up is joining forces with Microsoft to enlarge its innovative multiplatform datas and services engines to .Net environment.

The new system developed over the past six years by Chalmers University of Technology has notched up its first exit.

Microsoft Corp. executives, stressing the importance of collaboration in the company’s fast-growing global research program, called for more R&D partners among European universities and small companies.

Big pharma is hungry, and is paying biotechs breathtaking prices to fill its pipelines. This made for a heady atmosphere at BioEurope in Düsseldorf this week.